Zerit
Executive Summary
Sales of Bristol's newer nucleoside analogue were up 26% in the U.S. to $97 mil. for the quarter. International sales, however, fell 9% to $68 mil., reflecting the impact of currency and "slowing growth...relative to" Glaxo Wellcome's Combivir